RxDoctor Payments Data

Cindy Marriner

Family · Midland, TXNPI 1922008234

Payments from drug & device makers

$1,831in general payments, 2019–2025

Across 101 payments — averaging $18.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$372
  • AstraZeneca$351
  • Boehringer Ingelheim$176
  • Novo Nordisk$140
  • Pfizer$134
  • Sanofi-aventis U.S. LLC$131
  • plus $526 from 9 others

What the payments were for

  • Food & beverage$1,831100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,831 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$97,788
Medicare patients
308
Services billed
2,087

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin143$140,585
JanuviaSitagliptin Phosphate86$81,653
MyrbetriqMirabegron55$40,544
OzempicSemaglutide22$36,856
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$34,452
MounjaroTirzepatide29$32,015
TrulicityDulaglutide19$25,419
VascepaIcosapent Ethyl59$25,117
Tresiba Flextouch U-200Insulin Degludec23$23,541
TradjentaLinagliptin20$20,799
Tresiba Flextouch U-100Insulin Degludec20$11,564
EliquisApixaban18$11,144
Rosuvastatin Calcium564$9,740
Levothyroxine Sodium575$6,803
Atorvastatin Calcium354$6,173

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$176$161,384163 claims
MerckJanuvia$30$81,65386 claims
Lilly USA, LLCMounjaro, Trulicity$372$57,43448 claims
Astellas Pharma US IncMyrbetriq$106$40,54455 claims
GSKTrelegy Ellipta, Shingrix$125$39,13248 claims
Novo NordiskOzempic$140$36,85622 claims
PfizerEliquis$134$11,14418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in Midland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →